|
4. Scope of consolidation
Stevanato Group S.p.A. is the parent company of the Group and it holds, directly and indirectly, interests in the Group’s operating companies. The only change in the scope of consolidation for the year ended December 31, 2025 compared to previous periods presented is related to the inclusion of Stevanato India Private Limited, incorporated on February 23, 2025.
The Group’s scope of consolidation at December 31, 2025 and 2024 is as follows:
Subsidiaries
The consolidated financial statements of the Group include the following companies controlled by the parent company Stevanato Group S.p.A. directly or indirectly through the subsidiaries Stevanato Group International a.s., Balda Medical GmbH and Spami S.r.l.:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% equity interest |
Name |
|
Segment |
|
Description |
|
Country of incorporation |
|
2025 |
|
2024 |
Nuova Ompi S.r.l. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions and development of integrated solutions for the pharmaceutical industry |
|
Italy |
|
100% |
|
100% |
Spami S.r.l. |
|
Engineering |
|
Production plant and machinery |
|
Italy |
|
100% |
|
100% |
Perugini S.r.l. (*) |
|
Engineering |
|
Production of consumables and mechanical components for industrial machines |
|
Italy |
|
_ |
|
100% |
Stevanato Group International a.s. |
|
Holding |
|
Service/ Subholding company |
|
Slovakia |
|
100% |
|
100% |
Medical Glass a.s. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
Slovakia |
|
99.74% |
|
99.74% |
Ompi N.A. S. de RL de CV |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
Mexico |
|
100% |
|
100% |
Ompi of America inc. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production and sale of drug containment solutions and analytical services |
|
USA |
|
100% |
|
100% |
Ompi do Brasil I. e C. de Em. Far. Ltda |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
Brazil |
|
100% |
|
100% |
Ompi Pharm. Packing Techn. Co. Ltd |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
China |
|
100% |
|
100% |
Stevanato Group Denmark A/S |
|
Engineering |
|
Production plant and machinery |
|
Denmark |
|
100% |
|
100% |
Medirio SA en liquidation |
|
Biopharmaceutical and Diagnostic Solutions |
|
Research and development |
|
Switzerland |
|
100% |
|
100% |
Balda Medical Gmbh |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of in-vitro diagnostic solutions and DDS |
|
Germany |
|
100% |
|
100% |
Balda C. Brewer Inc. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of in-vitro diagnostic solutions |
|
USA |
|
100% |
|
100% |
Balda Precision Inc. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production metal components |
|
USA |
|
100% |
|
100% |
Ompi of Japan Co., Ltd. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Sale of drug containment solutions |
|
Japan |
|
100% |
|
100% |
Stevanato India Private Limited |
|
Biopharmaceutical and Diagnostic Solutions |
|
Sale of drug containment solutions |
|
India |
|
100% |
|
_ |
(*) The merger of Perugini S.r.l. into Spami S.r.l. was completed and effective on January 1, 2025.
Non-controlling interests
The equity and the net profit attributable to non-controlling interests at December 31, 2025 related to Medical Glass a.s. in which the Group holds a 99.74% interest. For further details refer to Note 35.
|